IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT EXAMINING OPERATION

Applicant(s): Reddy Bandi PARTHASARADHI

Serial No: 10/509,141 Group Art Unit: 1624

Filed: September 27, 2004 Examiner: Rei Tsang SHIAO

Att. Docket No.: H1089/20013 Confirmation No.: 1984

For: NOVEL CRYSTALLINE FORMS OF CANDESARTAN CILEXETIL

IDS CERTIFICATION STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the concurrently filled Form PTO/SB/08a. Unless otherwise indicated herein, one copy of each reference is submitted herewith. No copies of U.S. patents or U.S. patent application publications are submitted herewith. 37 CFR § 1.98(a)(2)(ii). It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. No representation is made that the reference(s) is/are prior art with respect to this application.

This Information Disclosure Statement is being filed after the period specified in 37 CFR § 1.97(b), but before the mailing date of any of a final action under 37 CFR § 1.113, a Notice of Allowance under 37 CFR § 1.311 or an action that otherwise closes prosecution in the application. Authorization to charge the additional fee under 37 CFR §1.17(p) is granted in the concurrently filed Fee Transmittal Form.

Application No. 10/509,141 IDS Certification Statement dated July 19, 2007

July 19, 2007

Please charge or credit our Account No. 03-0075 as necessary to effect entry and/or ensure consideration of this submission. Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN, COHEN & POKOTILOW, LTD.

Joseph F. Murphy

Registration No. 58,313 Customer No. 03000

(215) 567-2010

Attorneys for Applicant(s)